This compound is a deuterium-substituted tetrabenazine (a VMAT2 inhibitor) with slower elimination half-life, and wasapproved by the U.S. Food and Drug Administration (FDA) in 2017 as a treatment for chorea in Huntington disease, making it potentially available for off-label use for tics. Here, SLC18A2 is linked to Huntington disease.